Research collaboration secured with Mayo Clinic
Open PDF
| Stock | Echoiq Ltd (EIQ.ASX) |
|---|---|
| Release Time | 12 Jun 2026, 9:02 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
Echoiq Ltd partners with Mayo Clinic for cardiac risk study
Key Points
- Research collaboration with Mayo Clinic to assess AI-driven cardiac risk in cancer patients
- Study targets the growing cardio-oncology sector
- Expected study completion and publication in the first half of CY2027
Full Summary
Echo IQ Limited, an AI and medical technology company, has entered into a research collaboration with Mayo Clinic to evaluate its proprietary Artificial Intelligence (AI) platform for cardiac risk stratification in oncology patients. The study, conducted at Mayo Clinic Arizona, aims to assess the AI model's ability to generate predictive risk scores for heart failure based on echocardiographic parameters in patients undergoing cancer therapy. The research is expected to be completed and published in the first half of CY2027, targeting the emerging cardio-oncology sector driven by increasing cancer survival rates and focus on treatment-related cardiovascular complications.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In